Molecular Pharmaceutics
[ASAP] Dumbbell-Shaped Antisense Oligonucleotide Prodrugs Showed Improved Antinuclease Stability and Anticancer Efficacy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00396
Molecular Pharmaceutics
[ASAP] XA pH-Responsive and Colitis-Targeted Nanoparticle Loaded with Shikonin for the Oral Treatment of Inflammatory Bowel Disease in Mice
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00550
Molecular Pharmaceutics
[ASAP] Development of PLGA Nanoparticles with a Glycosylated Myelin Oligodendrocyte Glycoprotein Epitope (MOG<sub>35–55</sub>) against Experimental Autoimmune Encephalomyelitis (EAE)
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00277
Molecular Pharmaceutics
[ASAP] Near-UV and Visible Light Degradation of Iron (III)-Containing Citrate Buffer: Formation of Carbon Dioxide Radical Anion via Fragmentation of a Sterically Hindered Alkoxyl Radical
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00501
Molecular Pharmaceutics
[ASAP] Co-administration of Transportan Peptide Enhances the Cellular Entry of Liposomes in the Bystander Manner Both In Vitro and In Vivo
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00537
Molecular Pharmaceutics
[ASAP] Modulating Macrophage Clearance of Nanoparticles: Comparison of Small-Molecule and Biologic Drugs as Pharmacokinetic Modifiers of Soft Nanomaterials
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00528
Molecular Pharmaceutics
[ASAP] Liposomal Amphotericin B Formulation Displaying Lipid-Modified Chitin-Binding Domains with Enhanced Antifungal Activity
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00388
Molecular Pharmaceutics
[ASAP] A Positron Emission Tomography Tracer Targeting the S2 Subunit of SARS-CoV‑2 in Extrapulmonary Infections
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00584
Molecular Pharmaceutics
[ASAP] Optimization and Characterization of Low-Molecular-Weight Chitosan-Coated Baicalin mPEG-PLGA Nanoparticles for the Treatment of Cataract
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00341
Molecular Pharmaceutics
[ASAP] Modeling of Particle Dissolution Behavior Using a Geometrical Phase-Field Approach
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00214